BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 11837384)

  • 1. HCMV pp67-mRNA detection by nucleic acid sequence-based amplification in renal transplant patients.
    Merlino C; Bergallo M; Gregori G; Sinesi F; Bollero C; Cavallo R
    New Microbiol; 2002 Jan; 25(1):1-8. PubMed ID: 11837384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a quantitative-competitive PCR for quantification of human cytomegalovirus load and comparison with antigenaemia, viraemia and pp67 RNA detection by nucleic acid sequence-based amplification.
    Bergallo M; Costa C; Tarallo S; Daniele R; Merlino C; Segoloni GP; Negro Ponzi A; Cavallo R
    Panminerva Med; 2006 Jun; 48(2):119-27. PubMed ID: 16953149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct quantification of human cytomegalovirus immediate-early and late mRNA levels in blood of lung transplant recipients by competitive nucleic acid sequence-based amplification.
    Greijer AE; Verschuuren EA; Harmsen MC; Dekkers CA; Adriaanse HM; The TH; Middeldorp JM
    J Clin Microbiol; 2001 Jan; 39(1):251-9. PubMed ID: 11136779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary report for the application of nucleic acid sequence-based amplification in detection of human cytomegalovirus (HCMV) late pp67 mRNA for diagnosis of HCMV infection.
    Pairoj W; Srichunrusami C; Chantratita W; Bodhiphala P; Sungkanuparph S; Vibhagool A
    J Med Assoc Thai; 2000 Mar; 83 Suppl 1():S28-34. PubMed ID: 10865403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of late pp67-mRNA by NASBA in peripheral blood for the diagnosis of human cytomegalovirus disease in AIDS patients.
    Blank BS; Meenhorst PL; Pauw W; Mulder JW; van Dijk WC; Smits PH; Roeles F; Middeldorp JM; Lange JM
    J Clin Virol; 2002 Jul; 25(1):29-38. PubMed ID: 12126719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: a prospective, randomized, controlled, open-label trial.
    Gerna G; Baldanti F; Lilleri D; Parea M; Torsellini M; Castiglioni B; Vitulo P; Pellegrini C; Viganò M; Grossi P; Revello MG
    Transplantation; 2003 Apr; 75(7):1012-9. PubMed ID: 12698090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of human cytomegalovirus (HCMV) pp67-mRNA and pp65 antigenemia in relation to development of clinical HCMV disease in renal transplant recipients.
    Degré M; Kristiansen KI; Rollag H; Holter E; Nordal KP
    Clin Microbiol Infect; 2001 May; 7(5):254-60. PubMed ID: 11422252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the NucliSens CMV pp67 assay for detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation.
    Hebart H; Rudolph T; Loeffler J; Middeldorp J; Ljubicic T; Jahn G; Einsele H
    Bone Marrow Transplant; 2002 Aug; 30(3):181-7. PubMed ID: 12189537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of CMV load in solid organ transplant recipients by pp65 antigenemia and real-time quantitative DNA PCR assay: correlation with pp67 RNA detection.
    Mengoli C; Cusinato R; Biasolo MA; Cesaro S; Parolin C; Palù G
    J Med Virol; 2004 Sep; 74(1):78-84. PubMed ID: 15258972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression dynamics of human cytomegalovirus immune evasion genes US3, US6, and US11 in the blood of lung transplant recipients.
    Greijer AE; Verschuuren EA; Dekkers CA; Adriaanse HM; van der Bij W; The TH; Middeldorp JM
    J Infect Dis; 2001 Aug; 184(3):247-55. PubMed ID: 11443549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of CMV disease in pediatric kidney transplant recipients: evaluation of pp67 NASBA-based pre-emptive ganciclovir therapy combined with CMV hyperimmune globulin prophylaxis in high-risk patients.
    Renoult E; Clermont MJ; Phan V; Buteau C; Alfieri C; Tapiero B
    Pediatr Transplant; 2008 Jun; 12(4):420-5. PubMed ID: 18466427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study.
    Gerna G; Baldanti F; Torsellini M; Minoli L; Viganò M; Oggionnis T; Rampino T; Castiglioni B; Goglio A; Colledan M; Mammana C; Nozza F; Daniele L;
    Antivir Ther; 2007; 12(1):63-72. PubMed ID: 17503749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pp67 mRNA assay in treatment and monitoring of cytomegalovirus disease in renal transplant patients in India.
    Wattal C; Joshi S; Gupta A; Sharma A; Oberoi JK; Prasad KJ; Rana DS; Bhalla A; Khullar D
    Transpl Infect Dis; 2004 Jun; 6(2):90-2. PubMed ID: 15522113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective comparison of PCR-based vs late mRNA-based preemptive antiviral therapy for HCMV infection in patients after allo-SCT.
    Hebart H; Lengerke C; Ljungman P; Paya CV; Klingebiel T; Loeffler J; Pfaffenrath S; Lewensohn-Fuchs I; Barkholt L; Tomiuk J; Meisner C; Lunenberg J; Top B; Razonable RR; Patel R; Litzow MR; Jahn G; Einsele H
    Bone Marrow Transplant; 2011 Mar; 46(3):408-15. PubMed ID: 20581879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of nucleic-acid-sequence- based amplification for the detection of cytomegalovirus infection in renal and liver transplant recipients.
    Goossens VJ; Blok MJ; Christiaans MH; van Hooff JP; Sillekens P; Höckerstedt K; Lautenschlager I; Middeldorp JM; Bruggeman CA
    Intervirology; 1999; 42(5-6):373-81. PubMed ID: 10702720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical utility of CMV early and late transcript detection with NASBA in bronchoalveolar lavages.
    Keightley MC; Rinaldo C; Bullotta A; Dauber J; St George K
    J Clin Virol; 2006 Dec; 37(4):258-64. PubMed ID: 16978918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human cytomegalovirus immediate-early mRNA detection by nucleic acid sequence-based amplification as a new parameter for preemptive therapy in bone marrow transplant recipients.
    Gerna G; Baldanti F; Lilleri D; Parea M; Alessandrino E; Pagani A; Locatelli F; Middeldorp J; Revello MG
    J Clin Microbiol; 2000 May; 38(5):1845-53. PubMed ID: 10790111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Application of nucleic acid sequence-based amplification in detection of cytomegalovirus mRNA of recipients after allogeneic peripheral blood stem cell transplantation].
    Xu HX; Liu YF; Tan EX; Cai JT
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1195-9. PubMed ID: 17204193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of expression of human cytomegalovirus pp67 late transcript in heart, lung, and bone marrow transplant recipients as determined by nucleic acid sequence-based amplification.
    Gerna G; Baldanti F; Middeldorp JM; Furione M; Zavattoni M; Lilleri D; Revello MG
    J Clin Microbiol; 1999 Apr; 37(4):902-11. PubMed ID: 10074499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of CMV transcripts for monitoring of CMV infections in transplant recipients.
    Gerna G; Baldanti F; Middeldorp J; Lilleri D
    Int J Antimicrob Agents; 2000 Dec; 16(4):455-60. PubMed ID: 11118857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.